Trastuzumab Deruxtecan
中文名称 | Trastuzumab Deruxtecan |
---|---|
中文同义词 | 德卢替康-曲妥珠单抗;曲妥珠单抗-德鲁替康;德曲妥珠单抗 |
英文名称 | Trastuzumab Deruxtecan |
英文同义词 | Trastuzumab Deruxtecan;Trastuzumab deruxtecan (solution);Fam-trastuzumab deruxtecan;DS-8201a|||VRN-101099|||DS 8201|||T-DXd;Enhertu |
CAS号 | 1826843-81-5 |
分子式 | |
分子量 | 0 |
EINECS号 | |
相关类别 | 医药原料 |
Mol文件 | Mol File |
结构式 |
Trastuzumab Deruxtecan 性质
储存条件 | Solution, -20°C, 2 years |
---|---|
溶解度 | 溶于乙腈 |
形态 | 固体 |
颜色 | 白色至米白色 |
Trastuzumab deruxtecan (1 pM-10 nM; 5 days) inhibits the growth of HER2‐positive KPL‐4 cells, with an IC
50
of 109.7 pM.
Trastuzumab deruxtecan (10 nM; 5 days) shows bystander killing effects in HER2‐negative MDA‐MB‐468 cells.
Cell Viability Assay
Cell Line: | KPL‐4 and MDA‐MB‐468 cells |
Concentration: | 1, 10, 100, 1000, 10000 pM |
Incubation Time: | 5 days |
Result: | Killed both HER2‐positive KPL‐4 cells and HER2‐negative MDA‐MB‐468 cells. |
Trastuzumab deruxtecan (3 mg/kg; a single i.v.) shows antitumor activity against not only HER2‐positive tumors but also HER2‐negative tumors under the co‐inoculated condition.
Trastuzumab deruxtecan (10 mg/kg; i.v. on days 0 and 7) inhibits the tumor growth in in EMT6-hHER2 syngeneic mouse model.
Animal Model: | Female BALB/c nude mice injected with NCI‐N87 and MDA‐MB‐468‐Luc cells |
Dosage: | 3 mg/kg |
Administration: | A single i.v. |
Result: | Almost all of the HER2‐positive and HER‐negative cells disappeared and there were little or no cancer cells remaining in the tumors. |
安全信息
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/08/19 | HY-138298A | Trastuzumab Deruxtecan Trastuzumab deruxtecan | 1826843-81-5 | 1 mg | 6400元 |
2024/08/19 | HY-138298 | Trastuzumab Deruxtecan Trastuzumab deruxtecan | 1826843-81-5 | 1mg(10mg/mL * 100μL in Aqueous solution) | 6400元 |